Massive FDA layoffs spark concerns over drug and device approvals, posing uncertainty in the Australian market

Thousands of employees at the U.S. Food and Drug Administration (FDA) were abruptly terminated on April 1 as part of Human Services (HHS) Secretary Robert F. Kennedy Jr.’s controversial push to make the agency “more efficient and accountable.” The drastic reduction in the FDA’s workforce threatens to cripple its ability to evaluate and approve innovative health technologies – a disruption that may inevitably have repercussions in Australia.

A recent study reported that out of 273 drugs approved by the FDA, 53.8% were subsequently approved by the Therapeutic Goods Administration (TGA). Another analysis revealed that of 206 new drugs approved by the FDA from 2017 through 2020, 78.6% were granted approvals by at least one other regulatory agency, including the TGA, Health Canada, or the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), with a median delay of 12 months following US approval.

The layoffs have sent shockwaves through the US healthcare industry, with former FDA commissioner Dr Robert Califf warning of dire consequences.

“The FDA as we’ve known it is finished, with most of the leaders with institutional knowledge and a deep understanding of product development and safety no longer employed. I believe that history will see this as a huge mistake,” Califf said.

The layoffs follow Kennedy’s announcement last week of an impending reduction in force across HHS, slashing approximately 10,000 positions, including 3,500 FDA employees. Since then, workers have been left in limbo, uncertain about the fate of the agency and its ability to uphold regulatory standards.

“I will be glad if I’m proven wrong, but even then, there is no good reason to treat people this way,” Califf added. “It will be interesting to hear from the new leadership how they plan to put ‘Humpty Dumpty’ back together again.”

The biopharmaceutical sector is beginning to sound the alarm. A spokesperson from the Pharmaceutical Research and Manufacturers of America (PhRMA) underscored the risks posed by such a dramatic upheaval, saying “We recognise the need to find efficiencies, but it’s critical the FDA has the expertise and capacity it needs to maintain its gold standard regulatory review. The rapid and substantial changes at FDA this week raise questions about the agency’s ability to fulfil its mission to bring new innovative medicines to patients.”

Industry leaders are calling for a unified response. Professor Craig Rayner, Director of Translational Medicine, Infectious Diseases Development at Moderna and Adjunct Professor at Monash University said “As FDA is in duress, now is the most important time for drug/vaccine developers to do the right thing. We all must act in solidarity with FDA mission, and continue to deliver best practice product development programs, continue to drive regulatory science innovations and continue to put patients first.”

Meanwhile, medtech industry groups AdvaMed and the American Medical Manufacturers Association have strongly opposed the cuts, warning that they will undermine accessibility and affordability of healthcare.

With thousands of FDA experts cast aside overnight, the global healthcare sector faces an unsettling reality and an uncertain regulatory landscape.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.